Traditional Chinese medicine health products face difficulties in transitioning online. Shouxiangu Pharmaceuticals: Striving to have top anchors promote products during the singles' day sales. | Earnings conference in focus.

①The demand for traditional Chinese medicine health products has not improved; ②Zhejiang Shouxiangu pharmaceutical is promoting singles' day sales through live streaming hosts; ③Multiple measures are taken to maintain product price stability; ④Online transformation still faces certain challenges.

cls.cnSep 11 08:13 ET

Tesla plans to launch FSD in China in the first quarter of next year. Institutions say that the intelligent driving industry has reached a critical point.

Tesla released a roadmap on September 5th, and plans to launch the Full Self-Driving (FSD) system in China and Europe in the first quarter of 2025. However, approval from regulators is still pending. Anxin Securities' Ma Liang believes that in recent times, multiple policies have been introduced to support the development of intelligent driving, and combined with car companies actively promoting urban NOA deployment, the inflection point of the intelligent driving industry has arrived. It is recommended to pay attention to related opportunities.

cls.cnSep 5 19:39 ET

The State Tobacco Monopoly Administration has released new regulations on electronic cigarettes, and there is expected to be further improvement in market share for leading companies.

The State Tobacco Monopoly Administration issued a notice on the revision and implementation of the Regulations on the Management of Electronic Cigarette Transactions. The notice mentions that the competent administrative department of tobacco monopoly of the State Council will establish a nationwide unified electronic cigarette trading management platform. Caitong Securities' Lv Mingzhang pointed out that in the long term, non-compliant products will gradually be cleared, and market share is expected to further concentrate, which is bullish for leading companies in production, brand and other aspects.

cls.cnSep 2 19:47 ET

Hybio Pharmaceutical's H1 revenue continues to decline. Are active pharmaceutical ingredients becoming a 'lifesaver' for large orders? | Interpretations

①In the first half of this year, the revenue decline trend of Hybio Pharmaceutical has not been stopped, and the net profit loss has narrowed to some extent; ②The revenue of the formulation sector continues to decline due to the impact of block orders for main products, and the revenue contribution of the active pharmaceutical ingredient sector has become the first; ③In the first half of this year, Hybio Pharmaceutical has made some efforts to alleviate the cash flow.

cls.cnAug 23 08:58 ET

Director of Shandong Jincheng Pharmaceutical Group investigated for suspected stock market manipulation. Q1 performance just turned around according to announcement.

On the evening of today, Shandong Jincheng Pharmaceutical Group announced that its actual controller and chairman, Zhao Yeqing, was under investigation for suspected illegal acts of market manipulation by the China Securities Regulatory Commission. Zhao Yeqing has been the chairman of Jincheng Pharmaceutical Group for 13 years. The last time he appeared in public was at the 3rd China Pharmaceutical and Chemical Conference two days ago. In Q1 of 2024, Jincheng Pharmaceutical Group has shown a good trend of reversing last year's poor performance.

cls.cnAug 16 10:45 ET

Guizhou Xinbang Pharmaceutical, the company that sold its products at a loss, is going to Hong Kong Stock Exchange.

The Hong Kong Stock Exchange IPO application wave may be imminent. Since May of this year, 22 companies have submitted IPO applications to the Hong Kong Stock Exchange, while the Shanghai and Shenzhen stock exchanges are still in a state of "0 acceptance" during the same period. As a member of the vast army of IPO applications, Taide Pharmaceutical (Zhejiang) Co., Ltd. (referred to as "Taide Pharmaceutical") is launching a sprint towards the Hong Kong Stock Exchange. The application materials showed that Taide Pharmaceutical mainly provides peptide new chemical molecular entity discovery synthesis (CRO) and peptide chemical production, manufacturing and control (CDMO) services to pharmaceutical companies. In the reporting period, Taide Pharmaceutical has already achieved profits. From 2021 to 2023.

wallstreetcnJun 3 22:59 ET